TY - JOUR T1 - The SPEED study: initial clinical evaluation of the Penumbra novel 054 Reperfusion Catheter JF - Journal of NeuroInterventional Surgery JO - J NeuroIntervent Surg SP - i74 LP - i76 DO - 10.1136/neurintsurg-2012-010585 VL - 5 IS - suppl 1 AU - Don Frei AU - Johannes Gerber AU - Aquilla Turk AU - Malia McPherson AU - Don Heck AU - Ferdinand Hui AU - Gregory Joseph AU - Reza Jahan AU - Laszlo Miskolczi AU - Jeffrey Carpenter AU - Thomas Grobelny AU - Jim Goddard AU - Raymond D Turner AU - Dan Huddle AU - Richard Bellon AU - Imran Chaudry Y1 - 2013/05/01 UR - http://jnis.bmj.com/content/5/suppl_1/i74.abstract N2 - Background and purpose Revascularization of acute ischemic stroke from a large vessel occlusion continues to be a challenge with current thrombectomy devices. The purpose of the SPEED study was to report the safety and effectiveness of the Penumbra 054 Reperfusion Catheter System in revascularizing large vessel occlusions. Methods In this retrospective multicenter study, data were collected from patients with angiographic evidence of large vessel occlusion treated with the Penumbra 054 device as the intended primary therapy. Clinical outcome data were collected with 90-day follow-up and the results were compared with those from the Penumbra Pivotal trial. Results Eighty-seven target vessels in 86 consecutive patients treated with the Penumbra 054 device were included. The Thrombolysis In Myocardial Infarction (TIMI) 2 or 3 revascularization rate was 91% compared with a reported 82% in the Penumbra Pivotal trial. This was accomplished in a median time of 20 min compared with 45 min in the Penumbra Pivotal trial (p<0.0001). Eighteen (21%) patients experienced an intracranial hemorrhage of which 12 (14%) were symptomatic. Good neurologic outcome (modified Rankin scores ≤ 2) at 90-day follow-up was achieved in 34.9% of patients compared with 25% reported in the Penumbra Pivotal trial. All-cause mortality was 25.6%. Conclusions These results suggest that the Penumbra 054 is a fast, safe and effective revascularization tool for patients experiencing ischemic stroke secondary to large vessel occlusive disease. Improvements in speed and effectiveness of revascularization probably contributed to improved outcomes. ER -